The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
These initiatives aim to improve access to healthcare for rare disease patients
Subscribe To Our Newsletter & Stay Updated